Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
Gastric Cancer Sep 26, 2017
Kimura Y, et al. - A prospective phase II study of trastuzumab plus S-1 without cisplatin was performed in elderly patients with HER2-positive advanced gastric cancer (AGC). Among elderly patients with HER2-positive AGC, trastuzumab in combination with S-1 alone demonstrated promising antitumor activity and manageable toxic effects as well as promising survival results.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
